Mabion, Mylan Signs Agreement
News Nov 19, 2016
Mabion SA has signed a long-term development and commercialization agreement with Mylan Ireland a wholly owned subsidiary of Mylan NV. The agreement gives Mylan exclusive rights to sell Mabion’s biosimilar of Mabthera/Rituximab (Mabion CD20) in all EU countries and non EU Balkan states. Mylan will support Mabion in Mabion’s effort to secure approval of Mabion CD20 by the European Medicine Agency.
Under the terms of the agreement and subject to certain conditions, Mylan will pay Mabion an upfront payment of US$10 million and additional milestone payments in the aggregate of up to US$35 million subject to filing and approval of marketing authorizations and commercial launch in key countries, as well as royalties based on annual net sales.
Maciej Wieczorek, PhD, CEO of Mabion, said: We’re excited to finalize this EU collaboration with a global player like Mylan, which has strong experience in generics and biosimilars. We are convinced that with our partner we will be able to ensure successful commercialization in EU after Mabion’s CD20 approval.
This partnership will benefit patients in EU, Mabion and Mabion’s shareholders. Plexus Ventures, a global pharmaceutical business development firm, advised Mabion S.A. on this transaction.
Source: Story from Mabion SA. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.